A myelodysplastic neoplasm with del(5q) treated with luspatercept uncovers unexplored mechanisms of action for the drug

医学 全血细胞减少症 来那度胺 骨髓增生异常综合症 菲格拉斯汀 中性粒细胞减少症 中止 无效红细胞生成 内科学 国际预后积分系统 骨髓 沙利度胺 贫血 阿扎胞苷 骨髓增生性肿瘤 外科 耐受性 红细胞生成 胃肠病学 骨髓纤维化 不利影响 化疗 多发性骨髓瘤 生物化学 基因 DNA甲基化 化学 基因表达
作者
Iraklis Patsialos,Christina‐Nefeli Kontandreopoulou,Dimitra Vlachopoulou,Christos Stafylidis,Stavroula Syriopoulou,Fani Kalala,Amalia Anastasopoulou,Marina Mantzourani,Panagiotis Diamantopoulos
出处
期刊:British Journal of Haematology [Wiley]
标识
DOI:10.1111/bjh.19708
摘要

We would like to report the unique case of a 79-year-old man with myelodysplastic syndrome (MDS) with low blasts and isolated 5q deletion (Khoury et al., 2022)1 who was effectively treated with luspatercept. During the previous 10 months, he had received care at another healthcare facility with epoetin alpha and filgrastim, followed by five cycles of azacitidine, with no response, and he presented to us with severe pancytopenia. His past medical history was unremarkable except for heterozygous sickle cell disease. His bone marrow showed dyserythropoiesis, hypolobulated megakaryocytes and micromegakaryocytes, 2% myeloblasts, with no ring-shaped sideroblasts, with cytogenetics being 45,X,-Y,del(5)(q12q33)[12]/45,X,-Y[8] and no genomic alterations by next-generation sequencing. The revised International Prognostic Scoring System score was 3.5 (intermediate risk). The patient was started on lenalidomide at 10 mg qd for 21 days in 28-day cycles, along with deferasirox and filgrastim but due to ongoing grade 4 anaemia, neutropenia and thrombocytopenia, the lenalidomide dose was reduced and, finally, discontinued after 6 months, while he was heavily transfusion-dependent (Figure 1A). He was then started on off-label luspatercept at 1 mg/kg SC, increased after two 21-day cycles to 1.33 mg/kg subcutaneously. After five doses with no need to titrate to the maximum dose, treatment was discontinued due to a normal haemoglobin level and increased platelet and neutrophil counts (Figure 1B). The patient continued to increase his blood counts even off treatment. Fourteen months after luspatercept discontinuation, his marrow showed no dyserythropoiesis, normally maturing megakaryocytes and granulocytes, and blasts <1%, with a normal karyotype (45,X,-Y[30]), requiring no treatment, except for deferasirox (Figure 1C). Myelodysplastic syndrome with del(5q) constitutes approximately 5% of MDS and typically affects women, presenting with erythropoietin-refractory macrocytic anaemia, dyserythropoiesis, normal or elevated PLT counts, giant platelets, hypolobulated micromegakaryocytes and variable neutropenia. It is characterized by prolonged survival and a lower progression rate to acute myelogenous leukaemia,2 as well as high erythroid responses to lenalidomide,3 with frequent dose adjustments due to haematological toxicity.4 Luspatercept is an erythroid maturation agent that enhances late-stage erythropoiesis, reducing aberrant Smad2/3 signalling by binding transforming growth factor beta (TGFβ) superfamily ligands.5 It has been approved for anaemia in erythropoietin-naïve, transfusion-dependent adults with lower risk MDS, but it has not been tested in del(5q) patients.6 Regarding our patient, a trial of luspatercept was deemed well justified, since he did not benefit from a 6-month course of lenalidomide and experienced worsening pancytopenia, requiring regular red blood cell transfusions. In conclusion, the above preclinical data on the complex actions of the SMAD–TGFβ pathway on different blood cells as well as the limited clinical data on the effects of luspatercept on inflammatory pathways provide indirect clues that luspatercept's mechanism of action is more complex than a simple enhancement of late-stage erythropoiesis, spanning different haematopoietic cells and pathways that may affect haematopoiesis and inflammation, as a whole. Nevertheless, this data are still inadequate to guide further investigations, outside the context of clinical trials. I.P. performed data analysis and interpretation and wrote the main text. C.-N.K. contributed to drafting and writing the text. D.V., C.S, F.K. and A.A contributed to drafting sections of the document. M.M. reviewed and approved the final version of the document. P.D. coordinated the report, performed abstract and full-text screening, reviewed and revised the main document. This report did not receive any specific grant from funding agencies. None of the authors have a conflict of interest to disclosure. Not applicable to this study. Written informed consent was obtained from the patient for publication of this letter to the editor, a copy of which is available for review by the Senior Editor of British Journal of Haematology. All procedures followed were in accordance with the Helsinki Declaration. In the presence report since there are no photographs of any part of the body that could identify the patient, the IC will not be uploaded. Data that support the findings of this report are available from Prof. Panagiotis Diamantopoulos upon reasonable request. Due to clinical and ethical restrictions, patient identifiable information are not publicly available.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木木完成签到 ,获得积分10
刚刚
量子星尘发布了新的文献求助10
刚刚
JamesPei应助科研通管家采纳,获得10
1秒前
彭于晏应助科研通管家采纳,获得10
1秒前
如意2023完成签到 ,获得积分10
1秒前
fomo完成签到,获得积分10
5秒前
nagi发布了新的文献求助10
8秒前
jfeng完成签到,获得积分10
10秒前
JN完成签到,获得积分10
18秒前
忐忑的书桃完成签到 ,获得积分10
19秒前
qaplay完成签到 ,获得积分0
19秒前
友好语风完成签到,获得积分10
20秒前
CLTTTt完成签到,获得积分10
21秒前
yk完成签到,获得积分10
23秒前
甜美的初蓝完成签到 ,获得积分10
27秒前
早安完成签到 ,获得积分10
31秒前
初昀杭完成签到 ,获得积分10
35秒前
量子星尘发布了新的文献求助10
37秒前
LIU完成签到 ,获得积分10
37秒前
39秒前
nianshu完成签到 ,获得积分0
40秒前
starwan完成签到 ,获得积分10
41秒前
松松发布了新的文献求助20
41秒前
hooddy123459发布了新的文献求助10
42秒前
wenhuanwenxian完成签到 ,获得积分10
46秒前
happy完成签到 ,获得积分10
50秒前
拾壹完成签到,获得积分10
58秒前
雪花完成签到,获得积分10
1分钟前
清风完成签到 ,获得积分10
1分钟前
雪花发布了新的文献求助10
1分钟前
秀丽笑容完成签到 ,获得积分10
1分钟前
江湖应助聪慧芷巧采纳,获得10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
Rjy完成签到 ,获得积分10
1分钟前
性感母蟑螂完成签到 ,获得积分10
1分钟前
ruochenzu完成签到,获得积分10
1分钟前
陈尹蓝完成签到 ,获得积分10
1分钟前
天道酬勤完成签到,获得积分10
1分钟前
1分钟前
仁爱的谷南完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022